Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors

Neuro-Oncology

Volumn 12, Issue 10, 2010, Pages 1043-1049

  Wang, Fan ^a   Zhou, Feng ^b   Kruh, Gary D ^c   Gallo, James M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Pharmacology ^*  (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Brain tumor; Partition coefficient; Pharmacokinetics; Vincristine

Indexed keywords

VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; MOUSE; NONHUMAN; PARTITION COEFFICIENT; STEADY STATE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CHROMATOGRAPHY, LIQUID; MASS SPECTROMETRY; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; VINCRISTINE;

EID: 78650138276     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq056     Document Type: Article

References (26)

1. Gidding CE, Kellie SJ, Kamps WA, et al. Vincristine revisited. Crit Rev Oncol Hematol. 1999;29:267-287.
2. Comis RL. Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer. Semin Oncol. 1986;13:40-44.
3. Finkel HE. Vincristine therapy. N Y State J Med. 1967;67:2474-2478.
4. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507.
5. Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro Oncol. 2004;6:300-305.
6. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
7. Jackson DV, Jr, Sethi VS, Spurr CL, et al. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res. 1981;41:1466-1468.
8. Kellie SJ, Barbaric D, Koopmans P, et al. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer. 2002;94:1815-1820.
9. Benyahia B, Huguet S, Decleves X, et al. Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol. 2004;66:65-70.
10. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 1998;58:5130-5136.
11. Huang R, Murry DJ, Kolwankar D, et al. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol. 2006;71:1695-1704.
12. Watanabe T, Suzuki H, Sawada Y, et al. Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J Hepatol. 1995;23:440-448.
13. Stefankova Z, Barancik M, Breier A. Overcoming of P-glycoprotein mediated vincristine resistance of L1210/VCR mouse leukemic cells could be induced by pentoxifyline but not by theophylline and caffeine. Neoplasma. 1996;43:11-15.
14. Gallo JM, Li S, Guo P, et al. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 2003;63:5114-5117.
15. Guo P, Wang X, Zhou F, et al. Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;809:273-278.
16. El Dareer SM, White VM, Chen FP, et al. Distribution and metabolism of vincristine in mice, rats, dogs, and monkeys. Cancer Treat Rep. 1977;61:1269-1277.
17. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.
18. Dantzig AH, de Alwis DP, Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev. 2003;55:133-150.
19. Roberts LM, Black DS, Raman C, et al. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience. 2008;155:423-438.
20. Sugiyama D, Kusuhara H, Lee YJ, et al. Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. Pharm Res. 2003;20:1394-1400.
21. Zhang Y, Schuetz JD, Elmquist WF, et al. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther. 2004;311:449-455.
22. Zhou Q, Gallo JM. In vivo microdialysis for PK and PD studies of anticancer drugs. AAPS J. 2005;7:E659-E667.
23. Benjamin RK, Hochberg FH, Fox E, et al. Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol. 2004;6:65-74.
24. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991;66:85-94.
25. van Tellingen O, Buckle T, Jonker JW, et al. P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br J Cancer. 2003;89:1776-1782.
26. Johnson DR, Finch RA, Lin ZP, et al. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res. 2001;61:1469-1476.